<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-2953</journal-id>
<journal-title><![CDATA[Revista Cubana de Endocrinología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Endocrinol]]></abbrev-journal-title>
<issn>1561-2953</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-29532019000100050</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Osteoporosis y tratamiento para la diabetes mellitus]]></article-title>
<article-title xml:lang="en"><![CDATA[Osteoporosis and treatment for diabetes mellitus]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navarro Despaigne]]></surname>
<given-names><![CDATA[Daysi Antonia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta Cedeño]]></surname>
<given-names><![CDATA[Alina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Endocrinología  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>50</fpage>
<lpage>53</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-29532019000100050&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-29532019000100050&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-29532019000100050&amp;lng=en&amp;nrm=iso"></self-uri></article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Impact of Type 2 Diabetes on Bone Fracture Healing]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Luyten]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[van der Schueren]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kerckhofs]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vandamme]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Front Endocrinol]]></source>
<year>2018</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lecka-Czernik]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetes, bone and glucose-lowering agents basic biology]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2017</year>
<volume>60</volume>
<page-range>1163-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wongdee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoporosis in diabetes mellitus: possible cellular and molecular mechanism]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Charoenphandhu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[World J Diabetes]]></source>
<year>2001</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>41-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lecka-Czernik Beata]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of anti-diabetic therapies on bone]]></article-title>
<source><![CDATA[Clin Rev Bone Miner Metab]]></source>
<year>2013</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-58</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vianna]]></surname>
<given-names><![CDATA[AGD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review article: effects of type 2 diabetes therapies on bone metabolism]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Barreto]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetol Metab Syndr]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>75</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vianna]]></surname>
<given-names><![CDATA[AGD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vildagliptin has thesame safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes a randomized controlled trial]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Silva de Lacerda]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Muniz Pechmann]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Polesel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cestari Marino]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Zeghbi Cochenski]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetol Metab Syndr]]></source>
<year>2017</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sedlinsky]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Molinuevo]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Cortizo]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Tolosa]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Felice]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Sbaraglini]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Schurman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone inrats]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2011</year>
<volume>668</volume>
<page-range>477-85</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Cortizo]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Sedlinsky]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[World J Diabetes]]></source>
<year>2016</year>
<volume>257</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>122-33</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colhoun]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Livingstone]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Looker]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Wild]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Lindsay]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[and on behalf of the Scottish Diabetes Research Network Epidemiology GroupHospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2012</year>
<volume>55</volume>
<page-range>2929-37</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Driessen]]></surname>
<given-names><![CDATA[JHM]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[RMA]]></given-names>
</name>
<name>
<surname><![CDATA[van Onzenoort]]></surname>
<given-names><![CDATA[HAW]]></given-names>
</name>
<name>
<surname><![CDATA[Lalmohamed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burden]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto-Alhambra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists A Population-Based Cohort Analysis]]></article-title>
<source><![CDATA[Calcif Tissue Int]]></source>
<year>2015</year>
<volume>97</volume>
<page-range>104-12</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dicembrini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Antenore]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dipeptidyl peptidase-4 inhibitors and bone fractures a meta-analysis of randomized clinical trials]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2474-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dicembrini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drugs for type 2 diabetes role in the regulation of bone metabolism]]></article-title>
<source><![CDATA[Clinical Cases Miner Bone Metab]]></source>
<year>2015</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bunn]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Uppuganti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[KIL]]></given-names>
</name>
<name>
<surname><![CDATA[Lumpkin]]></surname>
<given-names><![CDATA[CHK]]></given-names>
</name>
<name>
<surname><![CDATA[Kalaitzoglou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fowlkes]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of SGLT2 Inhibitors, compared with Insulin, on Diabetic Bone Disease in a mouse model of Type 1]]></article-title>
<source><![CDATA[Diabetes Bone]]></source>
<year>2017</year>
<volume>94</volume>
<page-range>141-51</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
